Serum bone sialoprotein: A marker of bone resorption in postmenopausal osteoporosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 61, Issue 7, 2001, Pages 513-521

  Shaarawy, M ^a,b   Hasan, M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b Roxy Building ^*  (Egypt)

Author keywords

Anti resorptive therapy; Bone resorption markers; Bone sialoprotein; Cytokines; Postmenopaucal osteoporosis

Indexed keywords

BIOLOGICAL MARKER; BONE SIALOPROTEIN; SIALOGLYCOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MIDDLE AGED; OSTEOLYSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BIOLOGICAL MARKERS; BONE RESORPTION; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SIALOGLYCOPROTEINS;

EID: 0035232090     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655101753218274     Document Type: Article

References (29)

1. Fisher LW, Whitson SW, Avioli LW, Termine JD. Matrix sialop-rotein of developina bone. J Biol Chem 1983; 258: 12723-7.
2. Oldberg A. Isolation and characterization of two sialoproteins present only in bone. Biochem J 1995; 232: 715-24.
3. Fisher LW, Hawkins GR, Tuross N, Termine JD. Purification and partial characterization of small proteo-glycans I and II bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem 1987; 262: 9702-8.
4. Heinegard D, Oldberg A. Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEBJ 1989; 3: 2042-51.
5. Chen J, Shapiro HS, Wrana JL, Reimers S, Heerche JNM, Sodekl. Localization of bone sialoprotein expression to sites of mineral tissue formation in fetal rat tissue by in situ hybridization. Matrix 1991; 11: 133-43.
6. Shapiro HS, Chen J, Wrana JL, Zhang Q, Blum M, Sodek J. Characterization of porcine bone sialoprotein: primary structure and cellular expression. Matrix 1993; 13: 431-40.
7. Hulteniby K, Reinholt FP, Norgard M, Oldberg A. Wendel M, Heinegara D. Distribution and synthesis of bone sialoprotein in metaphyseal bone of young rates show a distinctly different pattern from that of osteoprotein. Eur J Cell Biol 1994; 63: 230-9.
8. Fujisawa R, Butler WT, Brunn JC, Zhou HY, Kuboki Y. Differences in composition of cell-attachment sialoproteins between dentine and bone. J Dent Res 1993; 72: 1222-6.
9. Oldberg A, Franzen A, Heinegard D, Pierschbacher M, Rouslahti E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 1988; 263: 19433-6.
10. 3 potentiate bone resorption. J Biol Chem 1993; 268: 9901-7.
11. Fujisaiwa R, Nodasaka Y, Kaboki Y. Further characterization of interaction between bone sialoprotein (BSP) and collagen. Calcif Tissue Int 1995; 56: 140-4.
12. Hunter GK, Goldberg HA. Modulation of crystal formation by bone phosphoproteins; role of glutamic acid-rich sequences in the nucleation of hydroxapetite by bone sialoprotein. Biochem J 1994; 302: 175-9.
13. Bianco P, Fisher LW, Young MF, Termine JD, Gehron RP. Expression of bone sialoprotein (BSP) in human developing, skeletal and non-skeletal tissues as revealed by immuno-staining and in situ hybridization. Calcif Tissue Int 1991; 49: 421-6.
14. Masi I, Brandi MI, Gehron RP. et al. Biosynthesis of bone sialoprotein by human osteoclast like cell line (FLG29.1) J Bone Miner Res 1995; 10: 187-96.
15. Gaudiller C, Delmas PD, Chenu C. Bone sialoprotein stimulates in vitro bone resorption (Abstract T 280). J Bone Miner Res 1995;10 Suppl 1.
16. Seibel MJ, Voitge HW, Pecherstarfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, Ziegler R. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996; 81: 3289-94.
17. 2 can directly activate mature osteoclast. Calcif Tissue Int 1990; 46: 149-53.
18. Hill PA, Tamber A, Papaioannou S, Meikle MC. The cellular action of interleukin-11 on bone resorption in vitro. Endocrinology 1998; 139: 564-72.
19. Seydin SM, Kung VT, Daniloff KN, et al. Immunoassay for urinary pyridinoline, the new biomarker of bone resorption. J Bone Miner Res 1993; 8: 635-41.
20. Strong DD, Beacher AL, Wergidal JE, Linkhart TA. Insulin like growth factor-2 and transforming growth factor B regulate collagen expression in human osteoblast-like cells in vitro. J Bone Miner Res 1999; 6: 15-22.
21. Cannalis E, McCarthy J, Cenrella M. Growth factors and the regulation of bone remodeling J Clin Invest 1988; 81: 267-71.
22. 2 in bone remodeling: a review. Clin Orthop 1990; 250: 261-5.
23. Piggs BL, Melton LJ, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turn-over and increases in bone mass both determine antifracture efficacy. Bone 1996; 18: 1975-2015.
24. Fleisch H. Bisphosphonates: pharmacology. Semin Arthritis Rheum 1994; 23: 261-2.
25. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ. Evaluation of urinary hydroxy pyridinium cross link measurement as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991; 21: 310-9.
26. Pedrazzoni M, Alfano FS, Gatti C, et al. Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif Tissue Int 1995; 57: 25-9.
27. Blumsohn A. Naylor KE, Assiri AMA. Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonates therapy in Paget disease. Clin Chem 1995; 41: 1592-8.
28. Ettinger B, Genant HK, Steiger P, et al. Low dose micronized 17 β estradiol prevent bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 479-88.
29. Rosen CJ, Shesnut CH, Mallink NJ. The predictive value of biochemical marker of bone turnover for BMD in early post menopausal women treated with HRT or calcium supplementation. J Clin Endocrinol Metab 1997; 82: 1904-10.